For research use only. Not for therapeutic Use.
PT-179 is an orthogonal Thalidomide (HY-14658) derivative that targets cereblon without causing off-target degradation effects. PT-179 is able to specifically bind CRBN, form a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediate the degradation of the tagged protein. For example, PT-179 binds to the ubiquitin ligase substrate receptor cereblon by forming a complex with SD40 and efficiently degrades proteins N- or C-terminally fused to SD40 or SD36 (DC50 for eGFP: 4.5 nM and 14.3 nM). PT-179 can be used to develop compact protein degradation tagging platforms[1].
SD40 is a degradation tag specific for PT-179. PT-179 (1-10 μM; 24 h) can induce eGFP degradation in HEK293T cells. The higher the evolution degree of the degron variant, the stronger the degradation efficiency of the corresponding tagged protein[1].
| Catalog Number | I040012 |
| CAS Number | 2924858-25-1 |
| Synonyms | 2-(2,6-dioxopiperidin-3-yl)-5-morpholin-4-ylisoindole-1,3-dione |
| Molecular Formula | C17H17N3O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H17N3O5/c21-14-4-3-13(15(22)18-14)20-16(23)11-2-1-10(9-12(11)17(20)24)19-5-7-25-8-6-19/h1-2,9,13H,3-8H2,(H,18,21,22) |
| InChIKey | CCCSRHUSXCBFJZ-UHFFFAOYSA-N |
| SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)N4CCOCC4 |
